company background image
600211 logo

Tibet Rhodiola Pharmaceutical Holding SHSE:600211 Stock Report

Last Price

CN¥38.02

Market Cap

CN¥12.3b

7D

-2.4%

1Y

-6.6%

Updated

21 Nov, 2024

Data

Company Financials +

Tibet Rhodiola Pharmaceutical Holding Co.

SHSE:600211 Stock Report

Market Cap: CN¥12.3b

Tibet Rhodiola Pharmaceutical Holding Co. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tibet Rhodiola Pharmaceutical Holding
Historical stock prices
Current Share PriceCN¥38.02
52 Week HighCN¥45.12
52 Week LowCN¥26.95
Beta1.06
11 Month Change-3.89%
3 Month Change8.60%
1 Year Change-6.57%
33 Year Change-5.28%
5 Year Change114.76%
Change since IPO424.97%

Recent News & Updates

At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?

Sep 25
At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Sep 02
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Recent updates

At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?

Sep 25
At CN¥33.30, Is Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Worth Looking At Closely?

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Sep 02
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Could Easily Take On More Debt

Insufficient Growth At Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Hampers Share Price

Jul 29
Insufficient Growth At Tibet Rhodiola Pharmaceutical Holding Co. (SHSE:600211) Hampers Share Price

Investors Shouldn't Overlook Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Impressive Returns On Capital

Jul 12
Investors Shouldn't Overlook Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Impressive Returns On Capital

Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly

May 21
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Seems To Use Debt Rather Sparingly

Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings

May 03
Shareholders Will Be Pleased With The Quality of Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Earnings

Under The Bonnet, Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Returns Look Impressive

Mar 22
Under The Bonnet, Tibet Rhodiola Pharmaceutical Holding's (SHSE:600211) Returns Look Impressive

Shareholder Returns

600211CN HealthcareCN Market
7D-2.4%-2.9%-3.4%
1Y-6.6%-12.7%6.1%

Return vs Industry: 600211 exceeded the CN Healthcare industry which returned -12.7% over the past year.

Return vs Market: 600211 underperformed the CN Market which returned 6.1% over the past year.

Price Volatility

Is 600211's price volatile compared to industry and market?
600211 volatility
600211 Average Weekly Movement6.0%
Healthcare Industry Average Movement8.6%
Market Average Movement8.2%
10% most volatile stocks in CN Market12.6%
10% least volatile stocks in CN Market5.5%

Stable Share Price: 600211 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 600211's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999601Yuan Dong Guowww.xzyy.cn

Tibet Rhodiola Pharmaceutical Holding Co. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. It offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. The company was founded in 1999 and is based in Lhasa, China.

Tibet Rhodiola Pharmaceutical Holding Co. Fundamentals Summary

How do Tibet Rhodiola Pharmaceutical Holding's earnings and revenue compare to its market cap?
600211 fundamental statistics
Market capCN¥12.25b
Earnings (TTM)CN¥737.44m
Revenue (TTM)CN¥2.94b

16.6x

P/E Ratio

4.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600211 income statement (TTM)
RevenueCN¥2.94b
Cost of RevenueCN¥158.60m
Gross ProfitCN¥2.78b
Other ExpensesCN¥2.05b
EarningsCN¥737.44m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.29
Gross Margin94.61%
Net Profit Margin25.07%
Debt/Equity Ratio14.4%

How did 600211 perform over the long term?

See historical performance and comparison

Dividends

4.0%

Current Dividend Yield

67%

Payout Ratio